MannKind Corporation (FRA:NNFN)

Market Cap	714.41M -45.2%
Revenue (ttm)	297.21M +22.2%
Net Income	4.99M -78.7%
EPS	0.02 -80.0%
Shares Out	n/a
PE Ratio	143.07
Forward PE	50.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	189
Open	2.345
Previous Close	2.298
Day's Range	2.345 - 2.345
52-Week Range	1.934 - 5.242
Beta	n/a
RSI	45.78
Earnings Date	May 8, 2026

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 592
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NNFN

Financial Performance

In 2025, MannKind's revenue was $348.97 million, an increase of 22.23% compared to the previous year's $285.50 million. Earnings were $5.86 million, a decrease of -78.75%.

Financial numbers in USD